SCHEMBL3334028

SCHEMBL3334028

Cc1nnc(C)c(-c2c(F)cccc2Cl)c1-c1ccc2ccccc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 1/20 0.45
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45
PDE2A O00408 2/20 0.43
PDE10A Q9Y233 2/20 0.43
FABP3 P05413 1/20 0.41
FABP4 P15090 1/20 0.41
FABP5 Q01469 1/20 0.41
IKBKB O14920 1/20 0.39
ABL1 P00519 3/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 3/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PTGES O14684 6/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3329110 0.89 LMNA (0.40) SMN1; SMN2LMNAMAPK1HTTPDE2A
SCHEMBL13165374 0.81 NPC1 (0.44) SMN1; SMN2LMNAMAPK1HTTPDE2A
SCHEMBL3331683 0.80 CYP1A2 (0.43) SMN1; SMN2IKBKBCYP2C9ALDH1A1CYP1A2
SCHEMBL3333863 0.77 IKBKB (0.38) SMN1; SMN2IKBKBABL1CYP2C9ALDH1A1
SCHEMBL3311845 0.76 NPC1 (0.42) SMN1; SMN2LMNAMAPK1HTTPDE2A
SCHEMBL28233048 0.75 ESR1 (0.50) SMN1; SMN2IKBKBABL1CYP1A2
SCHEMBL3312845 0.75 RXFP1 (0.42) SMN1; SMN2LMNAMAPK1HTTPDE2A
SCHEMBL2348112 0.75 NPC1 (0.41) SMN1; SMN2LMNAMAPK1HTTPDE2A
SCHEMBL3334563 0.74 IKBKB (0.40) SMN1; SMN2IKBKBCYP2C9ALDH1A1CYP1A2
SCHEMBL68893 0.73 NPC1 (0.47) SMN1; SMN2PDE2APDE10AIKBKBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144674-A1 PYRIDAZINE DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2010-06-10 US claimed
EP-2077997-A1 PYRIDAZINE DERIVATIVES Syngeta Participations AG (CH) 2009-07-15 EP claimed
WO-2008049585-A1 PYRIDAZINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2008-05-02 WO claimed
US-20100144674-A1 PYRIDAZINE DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2010-06-10 US disclosed
EP-2077997-A1 PYRIDAZINE DERIVATIVES Syngeta Participations AG (CH) 2009-07-15 EP disclosed
WO-2008049585-A1 PYRIDAZINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144674-A1 PYRIDAZINE DERIVATIVES C3AR1, C1S, CBR3 SMN1; SMN2 4760/4885LMNA 3400/4885MAPK1 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.